Equillium
EQ
Equillium (EQ) news
Recent news
Equillium Q2 operating income USD -5.155 million vs. IBES estimate USD -6.14 million
AInvest Wire · Aug 13, 2026Equillium Q2 operating expenses USD 5.155 million
AInvest Wire · Aug 13, 2026Equillium Q2 EPS USD -0.04 vs. IBES estimate USD -0.05
AInvest Wire · Aug 13, 2026Equillium Inc: Piper Sandler initiates coverage with overweight rating; target price $20
Piper Sandler has initiated coverage on Equillium Inc (EQ), a biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory disorders, with overweight rating and target price , according to recent analyst reports. The firm's decision reflects confidence in…
AInvest Wire · Jul 13, 2026ImportantEQT shares down 6.8%, on track for a worst day since Feb
AInvest Wire · Jun 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.